A novel series of N-methyl/benzyl-substituted benzimidazolyl-linked para-substituted benzyl-based compounds containing 2,4-thiazolidinediones, dimethyl malonate (DMM), and diethyl malonate (DEM) 17–27 were designed, docked, synthesized, and evaluated for their antidiabetic activity studies. Structures of all the synthesized compounds were confirmed through ¹H NMR, ¹³C NMR, FTIR, and mass spectrometry. Four targeted compounds (17–18 and 22–23) showed good inhibitory potential in the range of 4.10 ± 0.01 to 9.12 ± 0.06 µM. Furthermore, synthesized compounds 17–27 were evaluated for their antioxidant potential and compared with standard ascorbic acid and results showed that compound 18 (EC₅₀ = 0.176 ± 0.002 mM) being the most active. Compounds 17–18 and 22–23 exhibited prominent antidiabetic as well as antioxidant activity. Compound 18 was considered a promising candidate for this series. The designed molecules were docked into α-glucosidase protein (PDB Code. 3TOP) to develop a correlation with the α-glucosidase inhibition studies and were also additionally docked into PPARγ proteins (PDB ID: 2PRG) with rosiglitazone (standard drug) to study their PPARγ binding affinity in comparison with rosiglitazone and to classify these compounds for their PPARγ agonistic behavior.

中文翻译：

---

新型苯并咪唑衍生物的合成，分子对接，α-葡萄糖苷酶抑制和抗氧化活性的研究

一种新颖的一系列ñ -甲基/苯甲基取代的苯并咪唑基联对含有2,4-噻唑烷二酮，丙二酸二甲酯（DMM）和丙二酸二乙酯（DEM） -取代的苄基类化合物17 - 27被设计，停靠，合成并评估其抗糖尿病活性研究。通过¹ H NMR，¹³ C NMR，FTIR和质谱确认所有合成的化合物的结构。四种目标化合物（17 – 18和22 – 23）在4.10±0.01至9.12±0.06 µM的范围内显示出良好的抑制潜力。此外，合成化合物17– 27被评估其抗氧化潜力，并与标准抗坏血酸进行比较，结果表明化合物18（EC ₅₀  = 0.176±0.002 mM）最具活性。化合物17 – 18和22 – 23表现出显着的抗糖尿病和抗氧化活性。化合物18被认为是该系列的有希望的候选人。将设计的分子对接至α-葡萄糖苷酶蛋白（PDB代码3TOP）以发展与α-葡萄糖苷酶抑制研究的相关性，另外还与罗格列酮（标准药物）对接至PPARγ蛋白（PDB ID：2PRG）以研究其分子。与罗格列酮比较具有PPARγ结合亲和力，并根据这些化合物对PPARγ的激动作用进行分类。